Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine vs. Midazolam for Rapid Relief of Suicide Risk in Depression
NCT01700829Phase 4Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Jun 2012
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ketamine in major depressive disorder (MDD), suicidal ideation, sponsored by New York State Psychiatric Institute. Started Jun 2012; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on NCT01700829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01700829.